Quell Therapeutics, a UK-based biotech firm, has initiated human trials for its innovative autologous CAR-Treg therapy, QEL-005, targeting rheumatoid arthritis and systemic sclerosis. This development follows the company’s decision to halt its previous lead program, QEL-001, aimed at enhancing organ transplant outcomes.
Transitioning Focus to QEL-005
The phase 1/2 CHILL trial of QEL-005 is designed to modulate immune responses in inflamed tissues and lymphoid structures. The trial will recruit participants across the UK, Germany, and Spain, with results anticipated in early 2024.
This strategic shift comes on the heels of Quell’s review of interim results from the QEL-001 trial, which prompted the company to pause its development. While it seeks a partner to continue work on QEL-001, Quell is redirecting its internal resources toward QEL-005. The company envisions QEL-005 as a potential ‘pipeline-in-a-product’ solution for diseases marked by complex autoimmune mechanisms.
A Differentiated Therapeutic Approach
Iain McGill, Quell’s chief executive, emphasized the unique approach of QEL-005, stating the aim is to “CHILL, not KILL.” This reflects a focus on restoring immune balance rather than solely depleting B-cells. QEL-005 is based on a CD19 CAR mechanism, which interacts not only with B-cells but also with T-cells and inflammatory macrophages.
Professor Christopher Buckley, the lead investigator for the CHILL trial at the University of Oxford’s Kennedy Institute of Rheumatology, highlighted the importance of CAR-T cells in treating autoimmune diseases. However, he noted that traditional CAR-T therapies often “kill” rather than regulate, making QEL-005’s focus on regulatory T-cells a novel and promising approach.
Insights from the Interim Results
In a recent update, Quell’s chief medical officer, Dr. Luke Devey, shared insights from the interim results of the QEL-001 trial. The findings suggest that while QEL-100 may not achieve “full operational tolerance” in solid organ transplantation, it has potential for helping patients reduce their reliance on immunosuppressants.
Calcineurin inhibitor (CNI) drugs, such as ciclosporin, and mTOR inhibitors like tacrolimus can lead to significant side effects, including increased susceptibility to infections, diabetes, and hypertension. Dr. Devey articulated that the interim LIBERATE data indicates QEL-001 has been well tolerated, demonstrating positive signs of durability, effective trafficking to the transplanted liver, and a suppressive Treg phenotype.
Future Implications for Organ Transplantation
The potential of QEL-100 to facilitate a reduction in immunosuppression to CNI-free, low-dose mTOR monotherapy for liver transplant recipients could represent a significant advancement in transplant medicine. This could enhance patient quality of life by minimizing the side effects associated with long-term immunosuppressive therapy.
The Broader Landscape of Biotech Innovation
As Quell Therapeutics pivots towards QEL-005, it reflects a broader trend within the biotech industry where companies are increasingly focusing on targeted therapies that balance immune responses rather than merely suppressing them. The dual approach of addressing both autoimmune diseases and transplant-related challenges underscores the versatility of CAR-Treg technology.
Conclusion
Quell Therapeutics is at a pivotal juncture, steering its focus towards a promising CAR-Treg therapy that could revolutionize treatment for autoimmune diseases. As the CHILL trial unfolds, the outcomes may not only redefine therapeutic strategies but also set a precedent for future innovations in the realm of immunotherapy. The journey ahead for Quell is both challenging and filled with potential, as it seeks to balance efficacy with safety in complex medical landscapes.
- Key Takeaways:
- Quell Therapeutics is launching human trials for QEL-005, a CAR-Treg therapy.
- The CHILL trial aims to target autoimmune diseases while seeking to maintain immune balance.
- QEL-001 has been paused, with plans to seek a partner for its further development.
- The potential of QEL-100 may facilitate reduced immunosuppression in transplant patients.
- The transition reflects a broader industry shift towards therapies that regulate rather than deplete immune cells.
Read more → pharmaphorum.com